189 related articles for article (PubMed ID: 31490101)
1. Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation.
Su Y; Song P; Wang H; Hu B; Wang J; Cheng MS
J Biomol Struct Dyn; 2020 Aug; 38(13):3825-3837. PubMed ID: 31490101
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulation and QM/MM calculation reveal the selectivity mechanism of type I 1/2 kinase inhibitors: the effect of intramolecular H-bonds and conformational restriction for improved selectivity.
Wang H; Gao Z; Song P; Hu B; Wang J; Cheng M
Phys Chem Chem Phys; 2019 Nov; 21(43):24147-24164. PubMed ID: 31657381
[TBL] [Abstract][Full Text] [Related]
3. Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors.
Han D; Wang H; Cui W; Zhang B; Chen BZ
Future Med Chem; 2020 Mar; 12(5):367-385. PubMed ID: 32064922
[No Abstract] [Full Text] [Related]
4. In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation.
Gao Y; Wang H; Wang J; Cheng M
J Biomol Struct Dyn; 2020 Sep; 38(14):4119-4133. PubMed ID: 31556340
[TBL] [Abstract][Full Text] [Related]
5. P21 activated kinase signaling in cancer.
Rane CK; Minden A
Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
[TBL] [Abstract][Full Text] [Related]
6. The subcellular localization of type I p21-activated kinases is controlled by the disordered variable region and polybasic sequences.
Sun X; Su VL; Calderwood DA
J Biol Chem; 2019 Sep; 294(39):14319-14332. PubMed ID: 31391252
[TBL] [Abstract][Full Text] [Related]
7. A computational approach to explore and identify potential herbal inhibitors for the p21-activated kinase 1 (PAK1).
Shahinozzaman M; Ishii T; Ahmed S; Halim MA; Tawata S
J Biomol Struct Dyn; 2020 Aug; 38(12):3514-3526. PubMed ID: 31448698
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives as Potent and Selective p21-Activated Kinase 4 (PAK4) Inhibitors.
Hao C; Zhao F; Song H; Guo J; Li X; Jiang X; Huan R; Song S; Zhang Q; Wang R; Wang K; Pang Y; Liu T; Lu T; Huang W; Wang J; Lin B; He Z; Li H; Li F; Zhao D; Cheng M
J Med Chem; 2018 Jan; 61(1):265-285. PubMed ID: 29190083
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors.
Gul M; Fakhar M; Najumuddin ; Rashid S
PLoS One; 2019; 14(11):e0225132. PubMed ID: 31738805
[TBL] [Abstract][Full Text] [Related]
10. p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation.
Siu MK; Kong DS; Ngai SY; Chan HY; Jiang L; Wong ES; Liu SS; Chan KK; Ngan HY; Cheung AN
PLoS One; 2015; 10(7):e0133467. PubMed ID: 26218748
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling.
Tabusa H; Brooks T; Massey AJ
Mol Cancer Res; 2013 Feb; 11(2):109-21. PubMed ID: 23233484
[TBL] [Abstract][Full Text] [Related]
13. Strategy and validation of a structure-based method for the discovery of selective inhibitors of PAK isoforms and the evaluation of their anti-cancer activity.
Song PL; Wang G; Su Y; Wang HX; Wang J; Li F; Cheng MS
Bioorg Chem; 2019 Oct; 91():103168. PubMed ID: 31400553
[TBL] [Abstract][Full Text] [Related]
14. Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation.
Arowosegbe MA; Amusan OT; Adeola SA; Adu OB; Akinola IA; Ogungbe BF; Omotuyi OI; Saibu GM; Ogunleye AJ; Kanmodi RI; Lugbe NE; Ogunmola OJ; Ajayi DC; Ogun SO; Oyende FO; Bello AO; Ishola PG; Obasieke PE
Curr Drug Discov Technol; 2020; 17(5):682-695. PubMed ID: 31441728
[TBL] [Abstract][Full Text] [Related]
15. Determination of potential selective inhibitors for ROCKI and ROCKII isoforms with molecular modeling techniques: structure based docking, ADMET and molecular dynamics simulation.
Bayel Secinti B; Tatar G; Taskin Tok T
J Biomol Struct Dyn; 2019 Jun; 37(9):2457-2463. PubMed ID: 30047850
[TBL] [Abstract][Full Text] [Related]
16. Rho family GTPase signaling through type II p21-activated kinases.
Chetty AK; Ha BH; Boggon TJ
Cell Mol Life Sci; 2022 Nov; 79(12):598. PubMed ID: 36401658
[TBL] [Abstract][Full Text] [Related]
17. Molecular modelling approaches predicted 1,2,3-triazolyl ester of ketorolac (15K) to be a novel allosteric modulator of the oncogenic kinase PAK1.
Shahinozzaman M; Ahmed S; Emran R; Tawata S
Sci Rep; 2021 Sep; 11(1):17471. PubMed ID: 34471161
[TBL] [Abstract][Full Text] [Related]
18. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
Shao YG; Ning K; Li F
World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
[TBL] [Abstract][Full Text] [Related]
19. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach.
Agarwal S; Kashaw SK
J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248
[TBL] [Abstract][Full Text] [Related]
20. Identification of Pak1 inhibitors using water thermodynamic analysis.
Biswal J; Jayaprakash P; Suresh Kumar R; Venkatraman G; Poopandi S; Rangasamy R; Jeyaraman J
J Biomol Struct Dyn; 2020 Jan; 38(1):13-31. PubMed ID: 30661460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]